OrigiMed, a China-based leading precision medicine company and Takeda, a global biopharmaceutical company announced their strategic partnership to develop a genomic-based precision medicine platform during the 3rd China International Import Expo.
Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions.
With fast advances in the medical industry, on May 11, 2019, the third OrigiMed Summit for Cancer Discovery: Immunotherapy and Targeted Therapy was successfully held in Guangzhou.
OrigiMed (Shanghai) Co., Ltd., (OrigiMed) has formally announced the completion of its Series B financing.
On September 21, 2018, the CSCO precision medicine international session with the theme of "All-Round Research by Experts for Further Study", hosted by the Chinese Society of Clinical Oncology (CSCO) and organized solely by OrigiMed Co., Ltd.
5th Floor, Building 3, 115 Xinjun Ring Road, Minhang District, Shanghai
Floor 4, Information Building 2, Zhaolou Road 3576 , Pujiang Town, Minhang District, Shanghai
400-821-9890
Service Hours:9:00-18:00 Monday to Friday (except statutory holidays)
zbservice@origimed.com
We will reply you as soon as we receive the email.
All rights reserved in © Copyright 2022 OrigiMed Ltd
Registration Number:沪ICP备16027109号-1